ESC: Edoxaban Bests Warfarin on Safety in VTE (CME/CE)

AMSTERDAM (MedPage Today) -- Edoxaban, a novel factor Xa inhibitor, met its primary endpoint in a noninferiority study that pitted it against warfarin for treatment of symptomatic venous thromboembolism.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news